The Setup:
Eli Lilly (
LLY) is capitalizing on a massive fundamental double-catalyst—including new broad Medicare coverage for its weight-loss drugs—to trigger an explosive move. The stock has carved out a massive Base-on-Base structure on the monthly chart. After a deliberate retail shakeout, it immediately recovered the 50-Day Moving Average, broke out, and cleanly retested the structural breakout level. It has now launched to new All-Time Highs on a 235% Relative Volume surge, displaying extreme relative strength as capital aggressively rotates out of tech and into defensive healthcare giants.
Tip: Use
ELIL for a 2x leveraged ETF.
Reasoning:
Eli Lilly (
LLY) is capitalizing on a massive fundamental double-catalyst—including new broad Medicare coverage for its weight-loss drugs—to trigger an explosive move. The stock has carved out a massive Base-on-Base structure on the monthly chart. After a deliberate retail shakeout, it immediately recovered the 50-Day Moving Average, broke out, and cleanly retested the structural breakout level. It has now launched to new All-Time Highs on a 235% Relative Volume surge, displaying extreme relative strength as capital aggressively rotates out of tech and into defensive healthcare giants.Tip: Use
ELIL for a 2x leveraged ETF.Reasoning:
- Stacked Base on Base Structure (5-month consolidation resting on a 15-month base)
- Retail Shakeout & 50MA Recovery (Cleared weak hands and regained institutional support)
- Structural Retest (Orderly pullback to confirm old resistance as new support)
- Breakout to All-Time Highs on 235% Rvol (Massive institutional volume footprint)
- Fundamental Double-Catalyst (European regulatory backing + Medicare GLP-1 expansion)
- Leverage Option: ELIL (2x ETF)
Get my trade ideas straight to your inbox.
👉 profitpunch.org
👉 profitpunch.org
免責事項
これらの情報および投稿は、TradingViewが提供または承認する金融、投資、取引、またはその他の種類の助言もしくは推奨であることを意図したものではなく、またこれらに該当するものでもありません。詳細は利用規約をご覧ください。
Get my trade ideas straight to your inbox.
👉 profitpunch.org
👉 profitpunch.org
免責事項
これらの情報および投稿は、TradingViewが提供または承認する金融、投資、取引、またはその他の種類の助言もしくは推奨であることを意図したものではなく、またこれらに該当するものでもありません。詳細は利用規約をご覧ください。